AGIO Quote, Financials, Valuation and Earnings

Blueprint Medicines has a net margin of -899.56% compared to Agios Pharmaceuticals's net margin of -34.13%. Agios Pharmaceuticals's return on equity of 62.58% beat Blueprint Medicines's return on equity of -24.43%.

Agios Pharmaceuticals has a consensus price target of $54.57, signalling upside risk potential of 76.95%. On the other hand Blueprint Medicines has an analysts' consensus of $126.48 which suggests that it could grow by 40.95%. Given that Agios Pharmaceuticals has higher upside potential than Blueprint Medicines, analysts believe Agios Pharmaceuticals is more attractive than Blueprint Medicines.

Agios Pharmaceuticals has a beta of 0.903, which suggesting that the stock is 9.686% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.575, suggesting its less volatile than the S&P 500 by 42.472%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

Agios Pharmaceuticals quarterly revenues are $10.7M, which are smaller than Blueprint Medicines quarterly revenues of $146.4M. Agios Pharmaceuticals's net income of -$96.5M is lower than Blueprint Medicines's net income of -$50M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 2.72x while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 48.68x versus 11.18x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of -899.56% compared to Agios Pharmaceuticals's net margin of 1.4%. Agios Pharmaceuticals's return on equity of 62.58% beat Bruker's return on equity of 6.78%.

Agios Pharmaceuticals has a consensus price target of $54.57, signalling upside risk potential of 76.95%. On the other hand Bruker has an analysts' consensus of $68.42 which suggests that it could grow by 57.46%. Given that Agios Pharmaceuticals has higher upside potential than Bruker, analysts believe Agios Pharmaceuticals is more attractive than Bruker.

Agios Pharmaceuticals has a beta of 0.903, which suggesting that the stock is 9.686% less volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.406%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.46% to investors and pays a quarterly dividend of $0.05 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Agios Pharmaceuticals quarterly revenues are $10.7M, which are smaller than Bruker quarterly revenues of $979.6M. Agios Pharmaceuticals's net income of -$96.5M is lower than Bruker's net income of $13.7M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 2.72x while Bruker's PE ratio is 57.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 48.68x versus 1.93x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Organon & has a net margin of -899.56% compared to Agios Pharmaceuticals's net margin of 6.85%. Agios Pharmaceuticals's return on equity of 62.58% beat Organon &'s return on equity of 397.42%.

Agios Pharmaceuticals has a consensus price target of $54.57, signalling upside risk potential of 76.95%. On the other hand Organon & has an analysts' consensus of $20.00 which suggests that it could grow by 37.36%. Given that Agios Pharmaceuticals has higher upside potential than Organon &, analysts believe Agios Pharmaceuticals is more attractive than Organon &.

Agios Pharmaceuticals has a beta of 0.903, which suggesting that the stock is 9.686% less volatile than S&P 500. In comparison Organon & has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Organon & offers a yield of 7.69% to investors and pays a quarterly dividend of $0.28 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Organon & pays out 34.38% of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Agios Pharmaceuticals quarterly revenues are $10.7M, which are smaller than Organon & quarterly revenues of $1.6B. Agios Pharmaceuticals's net income of -$96.5M is lower than Organon &'s net income of $109M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 2.72x while Organon &'s PE ratio is 4.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 48.68x versus 0.59x for Organon &. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -899.56% compared to Agios Pharmaceuticals's net margin of -2357.27%. Agios Pharmaceuticals's return on equity of 62.58% beat Palatin Technologies's return on equity of --.

Agios Pharmaceuticals has a consensus price target of $54.57, signalling upside risk potential of 76.95%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 900%. Given that Palatin Technologies has higher upside potential than Agios Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Agios Pharmaceuticals.

Agios Pharmaceuticals has a beta of 0.903, which suggesting that the stock is 9.686% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Agios Pharmaceuticals quarterly revenues are $10.7M, which are larger than Palatin Technologies quarterly revenues of $350K. Agios Pharmaceuticals's net income of -$96.5M is lower than Palatin Technologies's net income of -$2.4M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 2.72x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 48.68x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.